The Weight-Loss War Just Turned Into a Partnership

Novo Nordisk and Hims & Hers settle a patent fight and strike a deal to sell branded GLP-1 drugs via telehealth

14 Apr 2026

When a lawsuit becomes a distribution agreement in a matter of weeks, the law is rarely the point. On March 9th, 2026, Novo Nordisk and Hims & Hers announced a deal to sell branded GLP-1 medications, including injectable and oral forms of Wegovy and Ozempic, through Hims & Hers' telehealth platform. The settlement resolved a patent suit Novo had filed against the company after Hims & Hers signalled its intention to market a compounded version of Novo's oral Wegovy pill.

The terms have a familiar shape: the smaller party drops its lower-cost alternative and pledges allegiance to the branded product; the larger party gains a channel and drops the litigation. Compounded semaglutide will remain available through Hims & Hers only in clinical edge cases where no branded option is deemed appropriate. Mass promotion is over.

Novo's urgency is understandable. On April 1st, 2026, the FDA approved Eli Lilly's once-daily oral weight-loss pill, adding competitive pressure to a market Novo had long dominated. Access to Hims & Hers' 2.5 million subscribers is not merely convenient; it is strategically important. Analysts at BMO Capital Markets expect a positive revision to Novo's financial outlook as prescription volumes respond to the expanded reach.

For Hims & Hers, the calculation was becoming uncomfortable. US regulators had been issuing enforcement warnings to telehealth platforms promoting compounded GLP-1 copies. Government pricing reforms had also narrowed the price gap between branded and compounded versions, eroding the commercial logic of the alternative. Pivoting toward FDA-approved products, supported by a membership program starting at $149 per month, offers a more defensible position.

The broader pattern is clear. Novo has already partnered with Ro, WeightWatchers, and LifeMD through its Wegovy subscription program. The Hims & Hers agreement adds another node to a distribution network being assembled with some urgency. Telehealth platforms, once seen as a threat to branded manufacturers, are being absorbed into the supply chain.

Whether patients benefit as much as shareholders remains an open question. Self-pay prices may be uniform across platforms, but access to GLP-1 treatment in the United States still depends heavily on what a subscriber can afford each month, and that arithmetic has not changed.